Dermata Posts Q2 Loss, Targets August 25 Debut for First Skincare Line
DRMA sits 16% above its 52-week low of $0.951 on light trading volume (0.3× avg).
Summary
Dermata Therapeutics reported Q2 2026 results with a $2.97M net loss and $4.4M in cash, providing runway into Q4 2026. The company confirmed its first product launch, Tome Foundational Treatment, for August 25, 2026.
Key Events · Earnings and Guidance · DRMA
-
Q2 2026 Financial Results
Net loss of $2.97 million on operating expenses of $3.01 million. Cash and equivalents stood at $4.4 million as of June 30, 2026, down from $7.5 million at year-end 2025.
-
Cash Runway into Q4 2026
Management expects current cash to fund operations into the fourth quarter of 2026, implying a need for additional capital before year-end.
-
First Product Launch Confirmed
Tome Foundational Treatment, a direct-to-consumer skincare product, will launch on August 25, 2026, representing the company's transition to a commercial-stage entity.
-
ATM Financing Proceeds
The company raised approximately $1.9 million through its at-the-market offering program during the first half of 2026, partially offsetting cash used in operations.
Analysis · DRMA · Life Sciences
Dermata disclosed its Q2 2026 financials, revealing a net loss of $2.97 million and cash of $4.4 million, which funds operations only into Q4 2026. The company also confirmed the August 25 launch date for Tome Foundational Treatment, its first commercial product, marking a critical pivot to revenue generation. While the launch is a positive milestone, the tight cash runway and ongoing losses underscore the urgency of commercial success.
At the time of this filing, DRMA was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.95 to $6.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.